Philip Mease, MD
Rheumatology · Seattle, WANPI 1336218171
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 14.7%. Among rheumatology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,380 payments — averaging $898.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$315K
- AbbVie$313K
- Novartis$222K
- Janssen Scientific Affairs, LLC$198K
- Pfizer$186K
- UCB, Inc.$172K
- plus $731K from 51 others
Across 594 payments — averaging $5465.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1.2M
- Amgen$348K
- Novartis$296K
- Janssen Research & Development, LLC$222K
- UCB SA$212K
- AbbVie$210K
- plus $735K from 13 others
What the payments were for
- Consulting fees$981,52546%
- Speaking & faculty fees$960,89045%
- Travel & lodging$162,0828%
- Food & beverage$32,6212%
- Education$1910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tremfya$265,267
- TALTZ$225,675
- SIMPONI ARIA$187,310
- COSENTYX$177,234
- Bimzelx$152,566
- Rinvoq$148,570
- Otezla$140,912
- XELJANZ$133,584
- STELARA$132,088
- Skyrizi$50,336
- Enbrel$35,990
- AIN457F_COSENTYX_IMMUNOLOGY$35,575
- Cimzia$30,815
- COSENTYX_COSENTYX_DERMATOLOGY$14,089
- ZEPBOUND$10,950
- AIN_COSENTYX_IMMUNOLOGY$10,031
- OLUMIANT$9,638
- REMICADE$9,556
- CRH_COSENTYX_IMMUNOLOGY$9,413
- KEVZARA$8,409
How this compares
$2,137,309 in reported general payments places this provider in the 95th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Seattle
- Stanford PengSeattle$3.5M
- Jane BucknerSeattle$57K
- Steven OvermanSeattle$17K
- Anthony KrajcerSeattle$14K
- Amish DaveSeattle$13K
- Namrata SinghSeattle$13K
- Peter MohaiSeattle$12K
- Myriam GuevaraSeattle$12K
- Kwang Hoon HanSeattle$11K
- Jeffrey CarlinSeattle$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.